Top Back to top

Outcome of patients with Intermediate risk Acute Myelogenous Leukemia in first remission and no detectable residual disease (MRD negative) transplanted with a haploidentical donor versus autografted

Acute Leukemia Working Party (ALWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Acute Myeloid Leukaemia (AML)
Short title:
Primary objective:
The primary endpoint will be the Overall Survival (OS)
Key inclusion criteria:
 Adult patients >18 years old.
 Transplant years between 2010-2019.
 First HSCT:auto-graft or Haploidentical transplantation.
 Acute Myelogenous Leukemia in 1st CR.
 Sources of stem cells PB, BM or PM+BM.
 Intermediate cytogenetics by MRC classification.
 MRD tested and negative (all means, immunophenotyping or molecular biology)
Principal investigator:
Norbert-Claude GORIN